Novo Nordisk announced plans for a longer phase III trial testing its investigational obesity drug CagriSema, with regulatory ...

Aardvark Therapeutics has followed up filings and speculation with a $94 million initial public offering, putting itself on ...

Large American pharmaceutical companies are showing a distinct trend never seen before: they are increasingly looking for ...

Amgen Inc. (NASDAQ: AMGN) stock is down about 1.4% in after-hours trading despite beating estimates on the top and bottom lines in its fourth quarter 2024 earnings report. Investors appear to be ...

Sitting at a market capitalization of $159 billion, Amgen (AMGN) is a biotech powerhouse. Founded in 1980, it is one of the biggest names in the healthcare and biotech industry, with a strong history ...

and in a phase 1 study achieved clinically significant body weight reductions over 12 weeks in people with obesity and without diabetes, according to Amgen. The drug was given as a subcutaneous ...

Amgen will continue to advance half of the combo, PRMT5 inhibitor AMG 193, for which it is running a mid-stage trial in ...

Given the number of comorbidities associated with obesity, the market's growth will impact the entire cardiometabolic disease ...

Pharm Exec’s 20th Annual Pipeline Report examines the emerging drug development trends and surging investments in five ...

Pancreatic cancer, one of the most aggressive and lethal types of cancer, continues to present significant challenges in both ...